Meriofert Pfs (Follicle-Stimulating Hormone, Luteinising Hormone)

FSH binds to receptors on ovarian granulosa cells, stimulating follicular growth and estradiol production, while LH binds to receptors on theca and luteal cells, promoting ovulation, luteinisation, and progesterone synthesis. In men, LH stimulates Leydig cells to produce testosterone, and FSH supports spermatogenesis. Together they restore the hormonal cascade required for gamete development.

The dose of Meriofert Pfs is individualized by the prescribing clinician based on the patient’s diagnosis, ovarian response, and treatment protocol. Dosing regimens are determined after baseline hormonal assessment and may be adjusted throughout the cycle according to ultrasound and estradiol monitoring.

Meriofert Pfs is intended for use before conception to induce ovulation or support follicular development. It is not recommended for continued use during an established pregnancy, and safety data for breastfeeding are limited. Treatment is typically stopped once pregnancy is confirmed, and clinicians should discuss risks with patients.

To order Meriofert Pfs, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if required) and any necessary import documentation.

Meriofert Pfs combines both FSH and LH in a single injectable formulation, which can simplify dosing compared with regimens that require separate FSH and LH preparations. Its EU‑origin manufacturing meets stringent quality standards, and the combined product may offer comparable efficacy to other recombinant gonadotropins while reducing the number of injections required.

Meriofert Pfs should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If the product must be transported, maintain the cold‑chain using validated insulated containers and temperature monitors.

Meriofert Pfs is administered by a healthcare professional via intramuscular or subcutaneous injection, typically into the thigh or abdomen. The injection site should be rotated according to standard clinical practice, and aseptic technique must be observed to minimise infection risk.

The most serious risks include ovarian hyperstimulation syndrome (OHSS), which can be life‑threatening if severe, multiple pregnancy, and rare thromboembolic events. Severe allergic reactions such as anaphylaxis have also been reported. Patients should be monitored closely for these complications, especially during the early phases of treatment.

Meriofert Pfs is contraindicated in individuals with known hypersensitivity to any component of the product, in patients with uncontrolled thyroid disease, and in women with ovarian cysts that could be aggravated by stimulation. It should also be avoided in pregnancy and in patients for whom ovarian stimulation is medically inadvisable.